The Trump administration is being urged to tackle imported generic pharmaceuticals, most of which are made in China, due to national security implications.

Sen. Rick Scott (R-FL), chairman of the Senate Special Committee on Aging, wants the Commerce Department to consider using Section 232 national security tariffs on imported generic medicines and their ingredients. Such a move would frame the U.S. pharmaceutical supply chain as a national security vulnerability rather than a purely economic issue.